Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Vivex Biologics Group Inc. maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is overseen by 1 distinct examiner, FISCHER, JOSEPH, within 1 distinct art unit. FISCHER, JOSEPH is the busiest examiner, responsible for 1 busiest examiner pending action.
The presence of 1 pending office action reflects a focused active docket. Because the company interacts with 1 distinct examiner and 1 distinct art unit, the administrative process is centralized. This 1 busiest examiner pending action constitutes the whole of the current active prosecution for the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18058112 | SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE | D' AMBROSIO, THEA | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18058112 | SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE | D' AMBROSIO, THEA | 10d overdue |
| 18074227 | SAP AND PEPTIDOMIMETIC COMPOSITIONS FOR REDUCING SYMPTOMS OF INFLAMMATION | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18074227 | SAP AND PEPTIDOMIMETIC COMPOSITIONS FOR REDUCING SYMPTOMS OF INFLAMMATION | FISCHER, JOSEPH | 1658 | §112 | Non-Final OA | — | Pending | Dec 02, 2022 |
| 18058112 | SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE | D' AMBROSIO, THEA | 1654 | §103§112 | Final Rejection | 10d overdue | Pending | Nov 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVivex Biologics Group Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Joseph Fischer has the most, with 1 of Vivex Biologics Group Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
